Related Experiment Videos

Therapy with macrolides in patients with cystic fibrosis

Allyson S Gaylor1, Joan C Reilly

  • 1Department Pharmacy Practice-Pediatrics, Texas Tech University Health Sciences Center, School of Pharmacy, Lubbock 79430, USA. Sopasg@ttuhsc.edu

Pharmacotherapy
|February 12, 2002
PubMed

Insights

Macrolide antibiotics show promise for cystic fibrosis (CF) patients by potentially reducing inflammation and Pseudomonas aeruginosa biofilm formation. These antibiotics are generally safe and may improve respiratory function in individuals with CF.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Cystic fibrosis (CF) is a lethal autosomal recessive disease affecting 1/2500 individuals, common in Northern European descent.
  • CF is characterized by chronic Pseudomonas aeruginosa infections and declining respiratory function.
  • The inflammatory component of CF is a significant area of research.

Purpose of the Study:

  • To investigate the potential of macrolide antibiotics in managing cystic fibrosis.
  • To explore macrolides' effects on inflammatory mediators and P. aeruginosa biofilm formation.

Main Methods:

  • Review of in vitro studies on macrolide antibiotics and P. aeruginosa.
  • Analysis of limited human studies examining macrolide use in CF patients.

Main Results:

  • In vitro studies demonstrate promising results for macrolides against P. aeruginosa.
  • Some human studies suggest improvements in respiratory function with macrolide treatment.

Conclusions:

  • Macrolide antibiotics may suppress inflammation and inhibit P. aeruginosa biofilm in CF.
  • Macrolides are generally safe and well-tolerated, offering potential therapeutic benefits for CF patients.

Related Concept Videos